Broadly neutralizing antibodies, or bnAbs, are a long‑standing goal of HIV vaccine research because they can disable many strains of the virus at once.

A new generation of engineered immune cell destroys cancer cells in mice 1 as effectively as conventional CAR-T-cell ...

Plants are a rich and renewable source of compounds used in medicines, food ingredients, and cosmetics. Since growing an ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...

– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

Scientists analyzing human and mouse pancreatic lymph nodes (PLNs) and spleens have identified a distinct subset of CD4 memory helper T cells associated with type 1 diabetes (T1D). Reported by ...

Epstein-Barr virus (EBV) infected and reprogrammed autoreactive B cells in patients with systemic lupus erythematosus (SLE) to become activated antigen-presenting cells. EBV-infected B cells in ...